|Nasdaq:||GOOG AMZN TSLA AMGN COST AAPL VRTX CELG SNDK GILD ADP CME ESRX SAVE SBUX DISH GPRO BEAV FB|
|Nyse:||ACT V IVV GS FDX IBM MMM TWC CMI PXD BA MON UNP KMB URI NSC UTX UPS ECL CVX|
|New Highs:||BLK IBB V SHW EQIX PPG AGN MCK IVV LMT PSA WHR RL ORLY SPG FDX BWLD CHTR BCR AMGN|
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.